What question did this study set out to answer?

To investigate factors predicting anemia response and ferritin dynamics in myelofibrosis patients treated with gecacitinib.

December 8, 2025BloodOpen Access

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

View Full Paper

Ask AI

Bookmark

To investigate factors predicting anemia response and ferritin dynamics in myelofibrosis patients treated with gecacitinib.
Conducted a post-hoc analysis of data from a phase 2 study.
Enrolled ruxolitinib-intolerant patients with myelofibrosis.
Assessed anemia response using transfusion dependency and hemoglobin levels.
47.5% of patients achieved an anemia response by week 24.
Anemia responders showed decreasing median ferritin levels from baseline.
JAK2 mutation was significantly associated with anemia response.

No takes yet. Share an insight, caveat, or question.

Post-hoc analysis reveals anemia response correlates with baseline ferritin and JAK2 mutation in ruxolitinib-intolerant myelofibrosis patients.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Post-hoc analysis reveals anemia response correlates with baseline ferritin and JAK2 mutation in ruxolitinib-intolerant myelofibrosis patients.